Ordering Recommendation
Aids in the investigation of virilizing endocrinopathies and in managing congenital adrenal hyperplasia in conjunction with other sex steroids. Not recommended for initial evaluation of polycystic ovarian syndrome.
Quantitative High Performance Liquid Chromatography-Tandem Mass Spectrometry
1-4 days  
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
Specimen Required
Patient Preparation
Specimen should be collected between 6-10 a.m.  
Serum separator tube or green (sodium or lithium heparin).  
Specimen Preparation
Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.3 mL) Also acceptable: EDTA plasma.  
Storage/Transport Temperature
Unacceptable Conditions
After separation from cells: Ambient: 24 hours; Refrigerated: 1 week; Frozen: 6 months  
Reference Interval
Effective August 19, 2013
Age Female Male
Premature Infants, 26-​28 weeks-​Day 4 0.92-​2.82 ng/mL 0.92-​2.82 ng/mL
Premature Infants, 31-​35 weeks-​Day 4 0.80-​4.46 ng/mL 0.80-​4.46 ng/mL
Full-​term Infants, 1-​7 days 0.20-​2.90 ng/mL 0.20-​2.90 ng/mL
8-​30 days 0.18-​0.80 ng/mL 0.18-​0.80 ng/mL
1-​5 months 0.06-​0.68 ng/mL 0.06-​0.68 ng/mL
6-​24 months Less than 0.15 ng/mL 0.03-​0.15 ng/mL
2-​3 years Less than 0.16 ng/mL Less than 0.11 ng/mL
4-​5 years 0.02-​0.21 ng/mL 0.02-​0.17 ng/mL
6-​7 years 0.02-​0.28 ng/mL 0.01-​0.29 ng/mL
8-​9 years 0.04-​0.42 ng/mL 0.03-​0.30 ng/mL
10-​11 years 0.09-​1.23 ng/mL 0.07-​0.39 ng/mL
12-​13 years 0.24-​1.73 ng/mL 0.10-​0.64 ng/mL
14-​15 years 0.39-​2.00 ng/mL 0.18-​0.94 ng/mL
16-​17 years 0.35-​2.12 ng/mL 0.30-​1.13 ng/mL
18-​39 years 0.26-​2.14 ng/mL 0.33-​1.34 ng/mL
40 years and older 0.13-​0.82 ng/mL 0.23-​0.89 ng/mL
Pre-​menopausal 0.26-​2.14 ng/mL Does Not Apply
Postmenopausal 0.13-​0.82 ng/mL Does Not Apply
Tanner Stage I 0.05-​0.51 ng/mL 0.04-​0.32 ng/mL
Tanner Stage II 0.15-​1.37 ng/mL 0.08-​0.48 ng/mL
Tanner Stage III 0.37-​2.24 ng/mL 0.14-​0.87 ng/mL
Tanner Stage IV-​V 0.35-​2.05 ng/mL 0.27-​1.07 ng/mL
Interpretive Data

Compliance Statement B: This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
CPT Code(s)
Component Test Code*Component Chart NameLOINC
2001639Androstenedione by TMS1854-9
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.